Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis

201494 citationsReview

Authors

The study revealed only a modest superiority of aflibercept 2 mg and ranibizumab 0.5 mg over other formulations and dosages.

Good health and well-being

Published in: British Journal of Ophthalmology

Volume 99, Issue 2, pp. 141-146

Field-Weighted Citation Impact: 11.62